Blood volume

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

Retrieved on: 
Monday, March 25, 2024
GFR, Commercialization, BVA, Customer experience, Iodine (125I) human albumin, Glomerular filtration rate, Blood volume, Pharmaceutical industry

Oak Ridge, TN, March 25, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for Volumex and Megatope from privately-held Iso-Tex Diagnostics, Inc. Daxor has also acquired the exclusive rights to Glofil, a drug that measures glomerular filtration rate (GFR), which Iso-Tex has been selling directly to its customer base.

Key Points: 
  • Daxor projects the acquisitions to be cash flow positive and accretive to earnings immediately upon transfer of the manufacturing.
  • This is due to the embedded revenue streams of the drugs and significantly higher margins that will be achieved with internalized production.
  • No payments will come due until manufacturing is fully transitioned to Daxor over the next 6-9 months.
  • The transaction is subject to customary conditions, including receipt of applicable regulatory approvals.

Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India

Retrieved on: 
Friday, March 22, 2024
Cardiac output, U.S. FDA, Internal bleeding, Partnership, System, Patient, Research, Trauma, Diarrhea, Hypovolemic shock, Mortality, Gastrointestinal bleeding, Manuscript, Laboratory, Blood volume, Standard of care, DRUGS, Clinical trial, Resuscitation, Safety, DCGI, Phase, Vomiting, Blood, FDA, Food, Shock (mechanics), Emerging market, Generic drug

Developed by Pharmazz for potential global use, Centhaquine is a resuscitative agent presently indicated for treating hypovolemic shock by Drugs Controller General of India (DCGI).

Key Points: 
  • Developed by Pharmazz for potential global use, Centhaquine is a resuscitative agent presently indicated for treating hypovolemic shock by Drugs Controller General of India (DCGI).
  • As per the agreement, Dr. Reddy's has received exclusive rights to market and distribute Centhaquine in India.
  • For patients with hypovolemic shock, I believe Dr. Reddy's is the best partner for Pharmazz to market Centhaquine, an innovative, first-in-class novel resuscitative agent, in India."
  • U.S. FDA clearance of our Phase III IND is an important milestone for Pharmazz and the potential future treatment of hypovolemic shock patients.

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Retrieved on: 
Monday, March 18, 2024
Department of Defence, Food and Drug Administration, Burn, Learning, Patient, BVA, Sale, Nature, Statistics, Investment, Note, LVAD, ICU, Duke, Form, Blood volume, NIH, Heart failure, Length of stay, American College, Operation, Hand, Health, Food, Sepsis, Acceleration, Letter, Proxy, Knowledge, Research, Hospital, Acquisition, CLIA, Clinical study design, Family, FDA, Consultant, Annual general meeting, Diagnosis, RCT, Financial statement, Growth, Syncope, Mortality, National Institutes of Health, Nursing care plan, Bangladesh Technical Education Board, Net, Government, Physician, Medicine, Pharmaceutical industry

We have never been more focused on our mission and goals. Every team member at Daxor sees both the remarkable strides the company has made over the past year solidifying its position as the global leader in blood volume measurement technology and the promise of what our rapid expansion means for both the company and the tens of millions of patients whose care we are eager to significantly improve. In every area 2023 and the strong start of 2024 has shown substantial progress for the company -- in revenue growth, new customer acquisitions, increasing utilization of our products by existing customers, next generation systems completed and under Food and Drug Administration (FDA) review, positive clinical studies, new patents granted and pending, successful National Institutes of Health (NIH) grant awards, Department of Defense (DoD) contracts awarded, and further research and development for groundbreaking products set to launch in subsequent fiscal years. I will detail below more in these areas but first wish to review why our company’s mission to commercialize the products that enable optimal patient care is so vital.

Key Points: 
  • Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh.
  • Many of these markers are costly, some are invasive, and none are accurate – in contrast to Daxor’s proven 98% accurate system.
  • Care teams cannot effectively treat what they do not correctly diagnose, so our rapid accurate diagnostic test is a game-changer.
  • Daxor has been reporting as an investment company under the Investment Company Act of 1940 since January 1, 2012.

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 13, 2024
Research, Hypersensitivity, Glucose, Deafness, Congestion, Ascites, Furosemide, Cerebral edema, Growth, Edema, Kidney, Ototoxicity, Diuresis, Tinnitus, Bruise, New Drug Application, Patient, Coma, Oliguria, History, NYHA, NDA, Benign prostatic hyperplasia, IDN, Blood volume, Embolism, Insurance, Thrombosis, Trial of the century, Heart failure, Investment, CO2, Urine, Dehydration, Creatinine, Urinary retention, Erythema, Pharmacy, Chronic kidney disease, Organic acid, Patent, Hypoproteinemia, Internationalized domain name, BUN, Huber loss, FDA, Government, GTN, Cirrhosis, Hepatic encephalopathy, Azotemia, Uric acid, Anuria, Pharmaceutical industry

BURLINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided a business update. 

Key Points: 
  • Product revenues were $6.1 million, and cost of product revenues were $1.8 million for the fourth quarter of 2023.
  • Research and development expenses were $3.3 million for the fourth quarter of 2023, compared to $2.3 million for the fourth quarter of 2022.
  • Selling, general and administrative expenses were $16.2 million for the fourth quarter of 2023, compared to $7.2 million for the fourth quarter of 2022.
  • scPharmaceuticals reported a net loss of $13.8 million for the fourth quarter of 2023, compared to $9.2 million for the fourth quarter of 2022.

New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload

Retrieved on: 
Tuesday, February 6, 2024
ICU, Diuretic, Mount Sinai Hospital, Patient, Cirrhosis, Ascites, FDA, Peritoneal cavity, Aquapheresis, Literature review, Food, Blood, Paracentesis, Series, Liver disease, Blood volume, Medical imaging

The publication, “Utilization of Aquapheresis Among Hospitalized Patients with End-Stage Liver Disease: A Case Series and Literature Review,” is a single-center retrospective case series featured in Clinical Transplantation .

Key Points: 
  • The publication, “Utilization of Aquapheresis Among Hospitalized Patients with End-Stage Liver Disease: A Case Series and Literature Review,” is a single-center retrospective case series featured in Clinical Transplantation .
  • The most common cause of liver disease was alcohol-related, with nine of the 14 patients presenting with alcohol-associated cirrhosis.
  • In this case series, Aquadex was shown to provide a potential additional solution to mitigate these clinical gaps.
  • Aquadex is proven to simply, safely, and precisely remove excess fluid from patients suffering from fluid overload who have not responded to conventional medical management, including diuretics.

NTT East Collaborates with Israeli Startup Binah.ai Ltd. for Safety and Health Management Solutions Using Wearable Devices

Retrieved on: 
Tuesday, January 16, 2024
Entrepreneurship, Heart rate, Health, Respiratory rate, Partnership, PPG, Acquisition, Safety, Acceleration, Wireless, Vital signs, Workforce, Blood volume, NTT, HRV, Ageing, Internet of things, Mobile phone

TEL AVIV, Israel, Jan. 16, 2024 /PRNewswire-PRWeb/ -- 

Key Points: 
  • The collaboration's inaugural effort introduces the integration of Binah.ai's proprietary technology, specifically the "Binah Connect", powered by the Binah.ai software, into NTT East's solution "Wearable Connect."
  • This integration is part of the innovative lineup aimed at monitoring employee health and safety to provide peace of mind.
  • NTT Israel (NTT Innovation Laboratory Israel), the focal point of NTT group and its Japanese and global clients to the Israeli innovation eco-system, initiated and facilitated the partnership.
  • While the solution also enables spot measurements using smartphone cameras, continuous monitoring is essential for safety and health management in fieldwork.

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Retrieved on: 
Thursday, January 4, 2024
Coma, Urine, Hepatic encephalopathy, Ascites, Kidney, Oliguria, Physician, Benign prostatic hyperplasia, Blood volume, Uric acid, Organic acid, Anuria, Urinary retention, NYHA, Furosemide, Cerebral edema, Hypersensitivity, Diuresis, Thrombosis, Deafness, Glucose, Azotemia, Ototoxicity, Creatinine, Tinnitus, Traction, BUN, Hypoproteinemia, Edema, Growth, Investment, Congestion, Huber loss, Patient, Bruise, Dehydration, CO2, Heart failure, Cirrhosis, Embolism, History, Erythema, Pharmaceutical industry

BURLINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced preliminary unaudited fourth quarter 2023 net FUROSCIX revenue in a range of $5.9 million to $6.1 million, representing sequential growth of 55% to 61% over $3.8 million net FUROSCIX revenue reported for the third quarter of 2023.

Key Points: 
  • For the full year 2023, the Company anticipates net revenue to be in a range of $13.4 million to $13.6 million.
  • The gross-to-net discount decreased to approximately 18% from launch through the end of Q4 versus 21% from launch through the end of Q3.
  • Inventory levels at the end of Q4 2023 were consistent with levels at the end of Q3 2023.
  • scPharmaceuticals will report its final and complete fourth quarter and full-year 2023 financial results in March.

Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

Retrieved on: 
Thursday, January 4, 2024
Food, Diuretic, Hypervolemia, Research, FDA, Blood volume, Blood, CRRC, Patient, Heart failure, Food and Drug Administration, ICU, Pharmaceutical industry

MINNEAPOLIS, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced it has received U.S. Food and Drug Administration (FDA) clearance for its specialty peripheral dual lumen extended length catheter (dELC).

Key Points: 
  • MINNEAPOLIS, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced it has received U.S. Food and Drug Administration (FDA) clearance for its specialty peripheral dual lumen extended length catheter (dELC).
  • The addition of a new 12 cm catheter provides clinicians who treat patients with fluid overload with an additional venous access option to use the company’s Aquadex® ultrafiltration system.
  • The dELC offers the performance capabilities of a central catheter from the periphery, and its unique inner coil design ensures consistent blood flow and prevents kinking.
  • The Aquadex system is cleared by the FDA for use in adults and pediatric patients weighing 20 kg (44 lbs.)

New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients

Retrieved on: 
Tuesday, November 28, 2023
Patient, Nephrology, Trust, Diuretic, Hypervolemia, FDA, Mortality, Blood volume, Blood, Overload, MD, Research, Ultrafiltration, Pharmaceutical industry

The publication, “ Using Aquapheresis with Continuous Hematocrit Monitoring to Guide Ultrafiltration ,” was featured in Pediatric Nephrology.

Key Points: 
  • The publication, “ Using Aquapheresis with Continuous Hematocrit Monitoring to Guide Ultrafiltration ,” was featured in Pediatric Nephrology.
  • 1
    The publication is a single-center case study review of pediatric patients with hypoalbuminemia and severe fluid overload.
  • Patients were treated with Nuwellis’ Aquadex® ultrafiltration therapy with continuous hematocrit monitoring to guide isotonic fluid removal.
  • “The continuous hematocrit monitoring function within the Aquadex provides unique and proprietary therapeutic direction, as demonstrated in this important publication.”
    Effectively managing fluid overload for pediatric patients is critical.

Virtual Internet announces Virtual 5G Enhanced Networking in support of Wearable Device Technology

Retrieved on: 
Wednesday, December 20, 2023
Cloud, Private, Wi-Fi, Invisibility, IPhone, Network, Wear OS, Smartphone, IOS, Collection, Medicine, Friends, Ethics, THG Ingenuity Cloud Services, Photoplethysmogram, Blood volume, Health, Artifact, Security, SAN, Internet, Rest, Android, Apple Watch, Anonymity, NFC, Device, Pedometer, PPG, Bluetooth, Tablet, Thermometer, Vital signs, Data collection, Skin, Mobile phone

SINGAPORE and SAN JOSE, Calif., Dec. 20, 2023 /PRNewswire/ -- Virtual Internet announced that Virtual 5G has now been enhanced to provide increased performance and security for platforms that incorporate wearable technologies. Virtual 5G enhancements are now fully automated and users do not need to make any special configuration changes to enable enhancements for their wearables. Virtual 5G enhancements allow wearables to deliver on their promise and purpose.

Key Points: 
  • SINGAPORE and SAN JOSE, Calif., Dec. 20, 2023 /PRNewswire/ -- Virtual Internet announced that Virtual 5G has now been enhanced to provide increased performance and security for platforms that incorporate wearable technologies.
  • Virtual 5G enhancements are now fully automated and users do not need to make any special configuration changes to enable enhancements for their wearables.
  • Technological advancement in wearable health devices has developed low-consumption and high-integration sensor technology with low-power high-performance battery technology and high processing chip technology.
  • Wearable Device sensors need connection to the network, yet Network issues of Bandwidth, Security, Privacy and Performance impact the utility of Wearable Health Devices.